UP!

CTRX $61.49

CTRX target price
61.49
0
0
Catamaran Corporation
Former type
Public
Traded as TSX: CCT
NASDAQ: CTRX
Industry PBM and Health informatics
Fate Acquired
Predecessor SXC Health Solutions
Successor UnitedHealth Group
Founded 1993
Defunct 2015 (2015)
Headquarters Schaumburg, Illinois, United States
Key people
Terrece C Burke, Chair
Mark A. Thierer (CEO)
Revenue $14,780.094 milIncrease49% 2013
Net income
$287.739 milIncrease138% 2013
Total assets $7,995.763 milIncrease8% 2013
Total equity $4,908.490 milIncrease6% 2013
Number of employees
4,000 (Dec 31, 2013)
1,433 (Dec.31,2011)
1,216 (Feb.25,2011)
Divisions informedRx
Healthcare IT Group
HBS Health Business Systems
Website www.catamaranrx.com

Catamaran Corporation (formerly SXC Health Solutions) is a Schaumburg, Illinois based pharmacy benefit management company that sells services related to pharmacy benefit management and medical record keeping to businesses in the United States. Working independently of the government and insurance companies allows it to operate as a third party verifier; the RxCLAIM online claim processing system allows for prescription drug claims to be processed online if the customer lives in and fills his/her prescription in the United States. SXC has three separate but interrelated business segments which deal with prescription drug programs. For 2013 23% of company revenue came from Cigna Corporation.

Most of the company's growth came in 2008 when it doubled in size; Between 2005 and 2010 revenue increased 3,400%. As a Canadian startup, the company received venture capital subsidies from the Canadian government in addition to private investments. These subsidies allowed the business to grow initially and establish its business model in advance of its initial public offering, which was offered through the NASDAQ exchange in 2009. The success of the mixed public and private approach in SXC's case has been called "perhaps the best example of the flexibility and the value added by the Canadian hybrid system." In 2013 company revenue increased by 49% thanks to a full year of prescription claims at the Catalyst division, and additional volumes from newly acquired Restat. On 30 March 2015, it was announced that Catamaran will be acquired by OptumRx (A UnitedHealth Group company).

Systems Xellence (SXC), founded in 1993, was a Canadian company that first went public in 1995 when it joined the TSX. Six years later, in 2001, it acquired ComCoTec, an Illinois-based software business. After going public on the NASDAQ stock market in 2006, the company shifted its headquarters from Milton, Ontario to Chicago, the city ComCoTec was based in. SXC was one of the first companies to build technology used in pharmacy benefit management.

In February 2008, eight months after the company changed its name to SXC Health Solutions, it acquired National Medical Health Card Systems, Inc. (NMHC) for US$143 million in a move that doubled its size and workforce. It is now known as InformedRx, a division of SXC. On December 19, 2008, the company also acquired Zynchros, an eight-year-old Seattle-based formulary management business.

SXC purchased private company MedfusionRx, Inc on December 2, 2010 for $100 million. Reasons for the acquisition include an interest in strengthening SXC's position in the speciality pharmacy market and improving cost cutting capabilities in the management of complex conditions and improving supportive care. MedfusionRx provides voice messaging services to people in all 50 US states as well as other clinical services to over 9000 patients. The messages have to do with medical treatment assistance including the delivery and refill reminders of medication and patient monitoring for people with chronic diseases. It was founded in 2003 in Birmingham, Alabama. Medfusion manages $270 million in drug spending.

In 2012, SXC agreed to buy rival Catalyst Health Solutions Inc. in a roughly $4.14 billion cash-and-stock deal. Shortly thereafter, SXC Health Solutions Corp. renamed the company, Catamaran Corp.

In 2015, Health insurer UnitedHealth Group agreed to buy pharmacy benefit manager Catamaran Corp in a deal worth about $12.8 billion.

SXC has three main business segments: InformedRx, Healthcare IT Group (HCIT), and Health Business Systems.

InformedRx is SXC Health Solution's pharmacy benefit management service. It deals with formulary administration, benefit plan design and management, pharmacy network management, drug utilization review, clinical services and consulting, reporting and information analysis, mail services and specialty pharmacy, and consumer web services.

Healthcare IT Group focuses on the technological aspects of the company. It includes the RxCLAIM, RxTRACK, and RxPORTAL customer interfaces, which support the electronic processing of prescriptions. It also includes pharmacy technology services (technology relied upon by application service providers), as well as Zynchros, a provider of formulary management tools.

Health Business Systems are management systems providers to retail, institutional or nursing home, and mail order pharmacy environments.

SXC Health Solutions has been used by various organizations, including Cigna, HealthSpring, PharMerica, TennCare, the Boston Medical Center HealthNet Plan, and Health Alliance of Michigan.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS

Ratings

2016-01-28 Upgrade JMP Securities Underperform to Market Perform
2015-04-22 Downgrade Maxim Group Buy to Hold
2015-04-08 Downgrade Argus Buy to Hold
2015-04-07 Downgrade Raymond James Outperform to Market Perform
2015-04-07 Downgrade Jefferies Group Buy to Hold $61.50
2015-04-07 Downgrade Raymond James Financial Inc. Outperform to Market Perform
2015-04-06 Downgrade BMO Capital Markets Outperform to Market Perform
2015-04-01 Upgrade Dougherty & Co Sell
2015-04-01 Downgrade Mizuho Buy to Neutral $57.00
2015-04-01 Downgrade Leerink Swann Outperform to Market Perform $60.00 to $61.50
2015-03-31 Downgrade FBR & Co. Outperform to Market Perform $61.50
2015-03-31 Boost Price Target CIBC Sector Outperformer $77.75
2015-03-31 Boost Price Target Scotiabank Sector Perform $61.50
2015-03-31 Boost Price Target Barclays Equal Weight $58.00 to $61.00
2015-03-31 Downgrade RBC Capital Sector Perform $61.50
2015-03-31 Downgrade SunTrust Buy to Neutral
2015-03-31 Downgrade Cowen and Company Outperform to Market Perform $57.00 to $61.50
2015-03-31 Downgrade William Blair Outperform to Market Perform
2015-03-31 Downgrade FBR & Co Outperform to Market Perform $61.50
2015-03-31 Boost Price Target Barclays PLC Equal Weight $58.00 to $61.00
2015-03-31 Downgrade Royal Bank Of Canada Sector Perform $61.50
2015-03-31 Downgrade SunTrust Banks Inc. Buy to Neutral
2015-03-30 Reiterated Rating FBR & Co. Outperform to Market Perform $61.50
2015-03-30 Reiterated Rating Credit Suisse Outperform to Neutral $61.00 to $61.50
2015-03-30 Reiterated Rating Credit Suisse Group AG Outperform to Neutral $61.00 to $61.50
2015-03-23 Initiated Coverage Mizuho Buy $57.00
2015-02-27 Reiterated Rating Deutsche Bank Hold $47.00 to $53.00
2015-02-27 Boost Price Target Leerink Swann Outperform $55.00 to $60.00
2015-02-27 Boost Price Target Barclays Equal Weight $51.00 to $58.00
2015-02-27 Reiterated Rating Deutsche Bank AG Hold $47.00 to $53.00
2015-01-21 Initiated Coverage Stephens Overweight
2015-01-08 Boost Price Target JPMorgan Chase & Co. Overweight $54.00 to $56.00
2015-01-06 Downgrade Morgan Stanley Equal Weight to Underweight $50.00
2014-11-03 Reiterated Rating Credit Suisse Outperform $54.00 to $55.00
2014-10-31 Reiterated Rating Deutsche Bank Hold $46.00 to $47.00
2014-10-31 Reiterated Rating Citigroup Inc. Neutral $48.00 to $51.00
2014-10-31 Boost Price Target FBR & Co. Outperform $51.00 to $53.00
2014-10-09 Reiterated Rating Morgan Stanley Equal Weight
2014-08-11 Initiated Coverage FBR & Co. Outperform $52.00
2014-08-04 Reiterated Rating Barclays Equal Weight $47.00 to $50.00
2014-08-04 Reiterated Rating Maxim Group Buy
2014-08-04 Boost Price Target Cowen and Company Outperform $54.00 to $56.00
2014-05-02 Reiterated Rating Barclays Equal Weight $47.00
2014-05-01 Reiterated Rating Dougherty & Co Buy
2014-04-22 Lower Price Target Cowen and Company $57.00 to $51.00
2014-04-21 Upgrade Ned Davis Research Neutral to Buy
2014-04-15 Upgrade Oppenheimer Market Perform to Outperform $50.00
2014-04-14 Lower Price Target JPMorgan Chase & Co. Overweight $55.00 to $48.00
2014-04-14 Reiterated Rating Jefferies Group Sell
2014-03-31 Lower Price Target Jefferies Group Buy $70.00 to $58.00
2014-03-05 Initiated Coverage Barclays Equal Weight $45.00
2014-02-28 Downgrade ISI Group Buy to Neutral $50
2014-02-28 Downgrade CIBC Outperform to Sector Perform
2014-02-28 Downgrade Evercore ISI Buy to Neutral $50.00
2014-02-27 Boost Price Target Cowen and Company $59.00 to $61.00
2014-02-18 Initiated Coverage Citigroup Inc. Buy to Neutral
2014-01-22 Initiated Coverage Argus Buy $65.00
2013-12-17 Downgrade Goldman Sachs Buy to Neutral $61.00 to $50.00
2013-11-27 Reiterated Rating Dougherty & Co Buy $57.00
2013-11-20 Initiated Coverage Deutsche Bank Hold $51.00
2013-11-01 Reiterated Dougherty & Company Buy $75 to $57
2013-11-01 Reiterated Rating Goldman Sachs Buy $69.00 to $61.00
2013-11-01 Lower Price Target Dougherty & Co Buy $75.00 to $57.00
2013-10-14 Reiterated Rating Morgan Stanley Hold $60.00
2013-10-14 Lower Price Target Evercore ISI Buy $65.00 to $60.00
2013-10-10 Initiated Coverage RBC Capital Outperform
2013-09-23 Downgrade Morgan Stanley Overweight to Equal Weight $60.00
2013-07-15 Upgrade ISI Group Buy to Strong Buy $62
2013-06-11 Reiterated ISI Group Buy $59.50 to $68
2016-01-28 Upgrade JMP Securities Underperform to Market Perform
2015-04-22 Downgrade Maxim Group Buy to Hold
2015-04-08 Downgrade Argus Buy to Hold
2015-04-07 Downgrade Raymond James Outperform to Market Perform
2015-04-07 Downgrade Jefferies Group Buy to Hold $61.50

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Funds

Major Shareholders

Name Relationship Total Shares Holding stocks
Reddon Philip 0.02%  (36660) CTRX /
Thorne Curtis 0.01%  (13850) CTRX /